{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.9","upperLimit":"17.7","value":"11.4"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"14","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Defined as the time from the first day of therapy to the date of death. If the patient was lost to follow-up, survival was censored on the last date the patient was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with advanced uterine carcinoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Carcinoma"},{"description":"Patients with advanced uterine carcinosarcoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Carcinosarcoma"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Month"}